# Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg

> **NCT01619878** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Acute Uncomplicated Falciparum Malaria

## Interventions

- **DRUG:** Artemether-lumefantrine (COA566)

## Key facts

- **NCT ID:** NCT01619878
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01619878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01619878, "Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01619878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*